Analyst ratings on Aldeyra Therapeutics (NASDAQ:ALDX)
There are currently 4 analysts ratings on Aldeyra Therapeutics with a consensus rating of Buy and a consensus price of $16 (133.58% upside).
The consensus estimates for Aldeyra Therapeutics (NASDAQ:ALDX) for the current year are $-1.71 EPS and for the following year are $-1.9 EPS.
Recent analyst ratings on Aldeyra Therapeutics
The most recent analyst ratings for Aldeyra Therapeutics include:
|11/15/2016||Cowen and Company||Reiterated Rating||Buy|
|9/26/2016||HC Wainwright||Initiated Coverage||Buy||$18.00|
|7/1/2016||Stifel Nicolaus||Initiated Coverage||Buy||$16.00|
|2/29/2016||Janney Montgomery Scott||Reiterated Rating||Buy|
|11/13/2015||Canaccord Genuity||Reiterated Rating||Buy||$15.00|
|3/25/2015||Chardan Capital||Initiated Coverage||Buy||$16.00|
Recent Insider Trades for Aldeyra Therapeutics
The most recent insider trades for Aldeyra Therapeutics (NASDAQ:ALDX) include:
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction|
|5/26/2016||Perceptive Advisors Llc||Major Shareholder||Buy||700,000||$5.00||$3,500,000.00|
|10/26/2015||Perceptive Advisors Llc||Major Shareholder||Buy||$50,000.00||$6.46||$323,000.00|
|10/22/2015||Perceptive Advisors Llc||Major Shareholder||Buy||18,020||$6.47||$116,589.40|
|10/20/2015||Perceptive Advisors Llc||Major Shareholder||Buy||37,145||$6.39||$237,356.55|
|8/7/2014||Martin Joseph Joyce||Director||Buy||$1,000.00||$3.95||$3,950.00|
|8/6/2014||C. Boyd Clarke||Director||Buy||3,000||$3.69||$11,070.00|
|5/7/2014||C. Boyd Clarke||Director||Buy||12,500||$8.00||$100,000.00|
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company’s aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.
Recent Trading activity for Aldeyra Therapeutics
Shares of Aldeyra Therapeutics (NASDAQ:ALDX) closed the previous trading session at $6.85 (up) (0.52) (8.30%) with (19.645K) shares trading hands.